Although it didn’t seem to attract too much attention last week there was a significant milestone in diabetes. Late this past Friday Sanofi (NYSE: SNY) announced "that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.”
Just as Lilly’s (NYSE: LLY) long-acting biosimilar Basaglar forever changed the dynamics of the long-acting insulin segment, Admelog will likely do the same in the short-acting segment.
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.